Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lyra TherapeuticsLYRA +2,400.00% 14-Day RSI is 14.54 as of Aug. 26, 2026. The stock has 3 warning signs investors should review. Among 1,420 Biotechnology companies, Lyra Therapeutics ranks better than 99.3% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Lyra Therapeutics 14-Day RSI Related Terms
LYRA vs ATXI, ZVSA, VBIO: 14-Day RSI Comparison
For the Biotechnology subindustry, Lyra Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyra Therapeutics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyra Therapeutics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Lyra Therapeutics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyra Therapeutics (LYRA) has a 14-Day RSI of 14.54 as of Aug. 26, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Lyra Therapeutics and its competitors. According to the industry distribution chart, Lyra Therapeutics ranks #10 out of 1420 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Lyra Therapeutics' 14-Day RSI too high?
Lyra Therapeutics' current 14-Day RSI is 14.54. The Biotechnology industry median 14-Day RSI is 51.66. Lyra Therapeutics' value of 14.54 is 71.9% below this industry median. Based on the distribution chart, Lyra Therapeutics ranks #10 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Lyra Therapeutics' 14-Day RSI compare to ATXI and ZVSA?
According to the Biotechnology industry distribution chart, Lyra Therapeutics ranks #10 out of 1420 companies for 14-Day RSI. This places Lyra Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 51.66. Lyra Therapeutics' value of 14.54 is 71.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 51.66, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lyra Therapeutics's current 14-Day RSI of 14.54 is 71.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Lyra Therapeutics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 51.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyra Therapeutics's current 14-Day RSI is 14.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lyra Therapeutics (LYRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.47, compared to a current price of $0.25 — trading 89.9% below its estimated fair value. The current 14-Day RSI is 14.54 and 71.9% below the Biotechnology industry median of 51.66. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Lyra Therapeutics (LYRA), the current 14-Day RSI is 14.54 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYRA has been successfully added to your 
